aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
© aVenture Investment Company, 2025. All rights reserved.
44 Tehama St, San Francisco, CA 94105
Privacy Policy
aVenture Investment Company ("aVenture") is an independent venture capital research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals.
While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision.
aVenture does not offer investment advisory services and is not registered as an investment adviser. The data provided by aVenture does not constitute recommendations or advice, whether by methodology or a statement written by a staff member of aVenture.
Links to external websites do not imply endorsement or affiliation with aVenture. References or links to providers offering the ability to invest in a primary or secondary transaction in a company are for convenience purposes only. They are not solicitations or offers to buy or sell an investment. Remember that past performance does not guarantee future results, and venture capital and private assets should be a contributory part of a diversified portfolio.
Atsena Therapeutics, founded with a mission to leverage genetic medicine to reverse or prevent blindness, is a clinical-stage gene therapy company. Their core focus is on developing innovative treatments for inherited retinal diseases. Atsena's pipeline includes therapies for conditions such as Leber Congenital Amaurosis 1 (LCA1), X-linked Retinoschisis (XLRS), and Usher Syndrome Type 1B (USH1B). The company employs advanced technologies like laterally spreading capsids and dual vector technology to enhance the delivery and efficacy of their gene therapies.
Notable figures affiliated with Atsena Therapeutics include experts on their Clinical and Scientific Advisory Boards, who bring significant experience in ophthalmology and genetic research. The company has garnered attention from prominent investors and partners in the biotech sector. A key achievement is their ongoing Phase I/II clinical trial for LCA1, which demonstrates their commitment to advancing treatments for inherited blindness. Atsena's work has the potential to significantly impact patients' lives by restoring vision and improving quality of life for those affected by genetic ocular conditions.
Operating Status
Active
Ownership Type(s)
Venture Capital
Main Product(s)
Gene Therapy
Technology
Biotech
Tags
Healthtech
Model Types
Software
Revenue Type(s)
Recurring
Customer Type(s)
Enterprise
Geographic Exposure
Global
When was Atsena Therapeutics founded?
Atsena Therapeutics was founded in 2019.
Where is Atsena Therapeutics's headquarters located?
Atsena Therapeutics's headquarters is located in Durham, NC, US.
When was Atsena Therapeutics's last funding round?
Atsena Therapeutics's most recent funding round was for $24.5M (USD) in October 2023.
How many employees does Atsena Therapeutics have?
Atsena Therapeutics has 55 employees as of Feb 5, 2024.
How much has Atsena Therapeutics raised to-date?
As of July 05, 2023, Atsena Therapeutics has raised a total of $87.6M (USD) since Oct 2, 2023.
Add Comparison
Total Raised to Date
$87.6M
USD
Last Update Oct 2, 2023
Last Deal Details
$24.5M
USD
Oct 2, 2023
Series Unknown
Total Employees Over Time
55
As of Feb 2024
Atsena Therapeutics Address
280 S. Magnum Street
Suite 350
Durham,
North Carolina
27701
United States
Source(s): This page includes data and analysis provided by the company, OpenAI, and our research analysts